PER-008-09已完成未知
Efficacy and Safety of Irbesartan/Amlodipine Fixed Combination Therapy Compared With Amlodipine Monotherapy in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy
sanofi-aventis Recherche & Development,0 个研究点目标入组 0 人开始时间: 2009年3月12日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 80（—）
入选标准
- •Men and women> 18 years old
- •Essential hypertension established
- •Treated with amlodipine 5 mg monotherapy for at least 4 weeks
- •With uncontrolled blood pressure defined as mean SBP> 145 mmHg evaluated by OBPM
- •Signed informed consent obtained before inclusion in the study
排除标准
- •Average SBP> 180 mmHg and / or average DBP> 110 mmHg measured in the doctor´s office at Visit 1
- •Known or suspected causes of secondary hypertension
- •Patients with bilateral arterial stenosis, renal artery stenosis in a solitary kidney, renal transplant or only a functioning kidney
- •Known contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination of both medications or history of angioedema related to the administration of an angiotensin II receptor antagonist or any combination of medications used.
- •Type 1 diabetes known
- •Known severe hepatic impairment [alanine aminotransferase (ALT) or aspaitan aminotransferase (AST)> 5 times the upper limit of normal or history of hepatic encephalopathy, esophageal varices, or portocaval derivation]
- •Known severe renal impairment (creatinine clearance <30 ml / mn)
- •Concomitant use of any antihypertensive treatment
- •Administration of any other investigative medication within 30 days prior to inclusion
- •Inability to obtain a valid automatic blood pressure measurement record
- •Presence of any severe medical or psychological condition that, in the opinion of the researcher, indicates that participation in the study is not in the best interest of the patient
- •Presence of any condition (eg geographic, social, etc.) that could restrict or limit patient participation for the duration of the study
- •Pregnant or breastfeeding women
- •Women with the potential to conceive children who are incapable or who do not wish to use an acceptable method to prevent pregnancy during the entire study period
研究者
相似试验
已完成
3 期
Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Amlodipine 5 mg MonotherapyHypertensionNCT00956644Sanofi406
已完成
3 期
Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Irbesartan 150 mg MonotherapyHypertensionNCT00957554Sanofi435
已完成
不适用
Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination ACTUA-I10 Essential (primary) hypertensionEssential (primary) hypertensionI10PER-115-08sanofi-aventis Recherche & Development,
已完成
3 期
Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension PatientsEssential HypertensionNCT05476354Handok Inc.271
已完成
3 期
Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension PatientsEssential HypertensionNCT05475665Handok Inc.157